Abingworth promotes Ken Haas and Vin Miles to partners

Abingworth has promoted Ken Haas and Vin Miles to partners. They are both based in the US where they source and manage deals including early stage and late stage venture capital, venture growth and public market investments as well as VIPEs (venture investments in public equities).

194 Views

Pixium Vision launches IPO on Euronext Paris

Pixium Vision has launched its Initial Public Offering on Euronext’s regulated market in Paris. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Proteon Therapeutics grabs $45 mln Series D

Proteon Therapeutics said Friday that it has raised $45 million in Series D financing. Abingworth led the round with participation from Deerfield Management Company, Pharmstandard International S.A., TVM Capital, Prism VentureWorks, Skyline Ventures, Intersouth Partners, MPM Capital, Devon Park Bioventures, Bessemer Venture Partners and the Vectis Healthcare and Life Sciences Fund. In addition to the funding, Tim Haines, a partner at Abingworth, and Dmitry Kobyzev, an investment manager at Inbio Ventures, have been added to Proteon Therapeutics’ board of directors. Headquartered in Waltham, Mass., Proteon Therapeutics is a biopharmaceutical firm focused on treating kidney and vascular diseases.

Pixium hires new CEO and director

Pixium has appointed Khalid Ishaque as CEO and director. Previously, Ishaque worked at Boston Scientific where he most recently served as general manager of its neuromodulation international business. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Pixium Vision raises funds led by Sofinnova

Pixium Vision, a developer of innovative retinal implant systems, has closed a Series A extension financing. This round was led by Sofinnova Partners, with support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance have joined the Pixium board of directors.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Avedro Completes $43m Series D

Avedro has completed a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro’s other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the board of directors.

Labcyte Closes $5.3m Financing

Labcyte, a privately-held company advancing acoustic liquid handling, has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors – Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Celgene to Acquire Avila Therapeutics

Summit, New Jersey-headquartered Celgene Corporation is to acquire Avila Therapeutics, a privately held biotechnology company. Avila is backed by Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. PRESS RELEASE Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through […]

Prosensa Raises Funding Round

Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, has raised €23 million (US$29.8 million) in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. PRESS RELEASE Prosensa, the Dutch biopharmaceutical […]

Takeda Pharmaceutical Buys VC-Backed Intellikine

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Intellikine Adds $4M in Milestone Payments

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

VC-Funded HBI Sells Antula Healthcare

Healthcare Brands International has sold its Antula Healthcare to specialty pharma company Meda AB for about $288 million. Healthcare Brands International was formed in 2006, and has raised capital from investors including Essex Woodlands, MVM Life Science Partners, Sofinnova Partners and Abingworth. The company bought Antual Healthcare in late 2007.

Clovis Oncology Raises $145 Million

Clovis Oncology, a developer of anti-cancer agents based in Boulder, Colo., secured $145 million in financing from Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company’s management team. Press release: Clovis Oncology, Inc., a company focused on acquiring, developing and commercializing innovative anti-cancer agents in […]

Algeta Raises $35 Million PIPE

Algeta ASA (OSE: ALGETA), a Norway-based cancer therapeutics company, has raised $35 million via a private placement of 22.3 million new shares. Venture capital firm Abingworth led the round. PRESS RELEASE Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that it has raised USD 35 million (NOK 245 million) through the Private Placement of […]

Hydra Biosciences Raises $22 Million in Series D Financing

Hydra Biosciences, a Cambridge, Mas.-based developer of novel ion channel drugs, raised $22 million in Series D financing led by MedImmune Ventures. Prior investors contributing follow-on commitments include Advanced Technology Ventures, Abingworth, Polaris, BioVenture Investors, Biogen-Idec Ventures, and Lilly Ventures in the Series D round. Hydra Biosciences has raised $47 million in previous rounds of […]

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget